Skip to main content

Saturday, July 20:  All UR Medicine facilities are open as scheduled and providing safe patient care, with a goal to return all clinical services to full efficiency by early next week.
Patients: click here for more information. Faculty/Staff: click here for information.


Monkeypox Treatment

Who should be considered for treatment with tecovirimat (Tpoxx) for Monkeypox virus?

Based on CDC guidelines:

  1. People with severe disease, such as bleeding, lesions that are merging together, sepsis, mental status changes, or other conditions requiring hospitalization.
  2. People who are at high risk of severe disease if they contract monkeypox, including 
    1. People with immunocompromising conditions, such as HIV/AIDS, leukemia, lymphoma, generalized malignancy (cancer), solid organ transplantation, therapy with certain medications, being a recipient of a stem cell transplant within 24 months post-transplant or more than 24 months but with graft-versus-host disease or disease relapse, or having autoimmune disease with immunodeficiency as a clinical component.
    2. Pediatric populations, particularly children younger than 8 years of age.
    3. People who are pregnant or breastfeeding.
    4. People with a history or presence of atopic dermatitis or with other active exfoliative skin conditions, such as eczema, burns, impetigo, varicella zoster virus (VZV) infection, herpes simplex virus (HSV) infection, severe acne, severe diaper dermatitis with extensive areas of denuded skin, psoriasis, or Darier disease (keratosis follicularis).
    5. People with one or more complications, such as secondary bacterial skin infection; gastroenteritis with severe nausea/vomiting, diarrhea, or dehydration; bronchopneumonia; concurrent disease or other comorbidities.
  3. People with atypical infection involving the eyes, mouth, or other areas of the body where Monkeypox virus infection might be a special hazard, such as the genitals or anus.

People over the age of 18 who have had a positive monkeypox test in the past 14 days and who have at least one skin lesion may also enroll in a clinical trial testing how well tecoviromat treats monkeypox infections. 

Learn more about the study.

For Patients

If you have tested positive for Monkeypox virus, have one of the conditions listed above, and would like to be treated with tecovirimat (TPOXX), please contact your primary care physician or the clinician who ordered your test. They will be able to refer you to URMC for treatment.

For Healthcare Providers Only

Patients with a confirmed positive Monkeypox virus test who meet eligibility criteria for tecovirimat (Tpoxx) treatment can be referred to the ID Clinic through UR Medicine’s electronic medical record (EMR); specify “Treatment for monkeypox” in the text. Providers who do not have access to UR Medicine’s EMR can refer patients through the Access Center (1-844-464-8762).